Alembic Pharmaceuticals Limited has officially appointed Mr. Rajkumar Baheti (DIN: 00332079) as Non-Executive Non-Independent Director, effective April 1, 2026. The appointment follows the successful conclusion of the postal ballot process on March 31, 2026, where shareholders demonstrated overwhelming support for the corporate governance decision.

Official Appointment Confirmation

The company formally communicated the appointment to BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The appointment was made based on the recommendation of the Nomination and Remuneration Committee and subsequent Board approval.

Director Profile and Qualifications

Mr. Rajkumar Baheti brings extensive professional expertise to the board. He is a Commerce graduate and fellow member of both the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India. With 44 years of professional experience in finance, he has specialized knowledge in corporate finance, financial governance, regulatory compliance, and complex financial matters.

Overwhelming Shareholder Support

The postal ballot results revealed exceptional shareholder confidence in the appointment decision. Shareholders approved the appointment of Mr. Rajkumar Baheti through an ordinary resolution with remarkable support across all voting categories.

Professional Fees Approval

Shareholders also approved the payment of professional fees to Mr. Rajkumar Baheti through a special resolution, demonstrating even stronger support with 99.83% approval rate.

Governance and Independence

The company has confirmed that Mr. Rajkumar Baheti is not related to any existing Directors or Key Managerial Personnel, ensuring independence in board composition. The appointment strengthens the company's governance framework with his extensive experience in financial matters and regulatory compliance.

Voting Process Details

The postal ballot was conducted entirely through remote e-voting facility provided by National Securities Depository Limited (NSDL) from March 2 to March 31, 2026. S. Samdani, Partner at Samdani Shah and Kabra, Company Secretaries, served as the scrutinizer, ensuring full compliance with Companies Act, 2013 and SEBI regulations.

Company Secretary Manisha Saraf formally communicated the results to stock exchanges, completing all regulatory requirements for the appointment process.

Alembic Pharmaceuticals Limited has officially notified stock exchanges regarding the resignation of a senior management personnel. The pharmaceutical company informed BSE and NSE about the departure of Mr. Nilesh Wadhwa from his position as Head - Formulation Business Development, effective March 31, 2026.

Regulatory Compliance and Documentation

The company filed the intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full compliance with regulatory requirements. Company Secretary Manisha Saraf signed the official communication to both stock exchanges on March 31, 2026.

Timeline of Resignation Process

The resignation process began when Mr. Wadhwa submitted his resignation letter on December 16, 2025, addressed to Managing Director Mr. Pranav Amin. In his letter, he expressed gratitude for the leadership and support received during his tenure, stating his intention to resign from the position of Head of International Business and Strategy.

Company's Response and Acceptance

Alembic Pharmaceuticals formally acknowledged and accepted the resignation through a letter dated December 31, 2025, signed by Shant Mankodi, Head-Human Resources. The acceptance letter confirmed that Mr. Wadhwa would be discharged from his duties effective March 31, 2026, after office hours.

The company noted that the acceptance letter was not a formal relieving letter, with the official relieving documentation to be provided upon settlement of dues and handover of responsibilities on the last working day.

Professional Transition

In his resignation communication, Mr. Wadhwa emphasized his continued commitment to the organization during the transition period and expressed appreciation for the opportunities for learning and professional growth. He assured the management of his support for a smooth transition process until his departure date.

The company has completed all necessary regulatory filings and documentation related to this senior management change, maintaining transparency with stakeholders and regulatory authorities.